Expression of Matrix Metalloproteinase-9 in Gastric Cancer

Prathipaa R 1, Priyathersini N 2, Thanka J 3

1. Pathology, ACS Medical College and Hospital, Chennai, IND
2. Pathology, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND
3. Pathology, Sree Balaji Medical College and Hospital, Chennai, IND

Corresponding author: Priyathersini N, priyathersinin@sirimachandra.edu.in

Abstract

Background

Matrix-metalloproteinase-9 (MMP-9) is expressed by a wide range of cells and plays a significant role in the regulation of the tumor microenvironment of various cancers including gastric cancer. This study aims at the correlation of MMP-9 expression in gastric cancer with existing prognostic factors.

Methods

The MMP-9 expression in gastric cancer was identified by immunohistochemistry using a monoclonal antibody in paraffin-embedded sections, correlated with various clinicopathological parameters, and statistically analyzed.

Results

MMP-9 expression in gastric cancer was significantly correlated with the grade, depth of invasion, and TNM stage (p-value = 0.003, 0.019, and 0.025, respectively). A significant difference in expression between tumor tissue and adjacent gastric mucosa (p-value = 0.000) was also observed. 100% negative expression was found in well-differentiated tumors and early gastric carcinoma (T1).

Conclusion

The study results suggest that MMP-9 expression could be a potential biomarker of aggressive gastric cancer and candidates for the possible diagnostic and prognostic tool.

Introduction

Gastric cancer is the malignant epithelial neoplasm that represents a biologically and genetically heterogeneous group of neoplasms with multifactorial etiologies. In the 1930s, gastric cancer was the leading cause of cancer-related death in the United States and Europe. Over the past 70 years, there is a dramatic decline in incidence and mortality in various parts of the world with the recent decline in non-cardia, intestinal type of adenocarcinomas, and a rising trend in proximal, diffuse-type adenocarcinomas in Western countries [1-3]. Currently, Gastric cancer ranks fifth most common cancer after lung, breast, colorectal, and prostate cancer worldwide. Gastric cancer is the third most common cause of cancer-related death worldwide in both sexes with 723,000 deaths annually. The highest estimated mortality rates are in Eastern Asia and the lowest in North America [4].

Matrix-metalloproteinases (MMPs) are a group of zinc-dependent enzymes present in the extracellular matrix of various tissues which plays a major role in the regulation of the tumor microenvironment. Among 23 human MMPs, MMP 2 and MMP-9 play a critical role in tumor invasion and angiogenesis because of their ability to degrade type IV collagen of basement membrane which forms the first barrier in the process of invasion, however, MMP-9 is 25 times more potent than MMP-2 [5]. MMP-9 is expressed by a wide range of cells including macrophages, neutrophils, and fibroblasts and its activity is regulated by cytokines, growth factors, and tissue inhibitors of matrix metalloproteinases (TIMP) [6]. MMP-9 also plays an important role in physiological conditions such as embryogenesis, tissue remodeling, and wound healing and pathological conditions such as inflammation, autoimmune diseases, and diabetes. It also plays an important role in immune cell function [7].

Studies show increased expression of MMP-9 which is associated with invasion, metastasis, and poor prognosis in various cancers including cervical, colorectal, ovarian, and breast cancer [8-11]. In gastric carcinoma, overexpression of MMP-9 is correlated with increased metastatic potential, TNM staging, lymphatic invasion, depth of tumor invasion, and overall survival [12]. MMP-9 contributes to tumor...
metastasis via the sonic hedgehog signaling pathway in gastric cancer [13]. Its role in Helicobacter pylori-induced gastric inflammation, ulceration, and carcinogenesis were also observed [14]. The objective is to study the expression of MMP-9 (matrix metalloproteinase-9) in gastric cancer and to correlate it with the existing prognostic factors.

**Materials And Methods**

The study includes 100 gastric carcinoma cases of total and partial gastrectomy specimens from the Department of Pathology, in a Tertiary care center, collected during the time period between January 2015 and December 2019. The Institutional Ethical Committee in Sri Ramachandra Institute of Higher Education and Research approved the study (Ethics Committee Number: CSP-MED/15/JAN/21/01). The study parameters include age, sex, tumor size, site, differentiation status, lymphovascular invasion, depth of invasion (T), node (N) metastasis, distant metastasis (M), and TNM stage. The MMP-9 expression was studied and correlated with the study parameters.

The gastrectomy specimens were immediately fixed in 10% phosphate-buffered formalin for 24 to 48 hours. After gross examination, the representative bits from the tumor and adjacent normal tissue are submitted for processing using an automatic tissue processor. Paraffin sections of 5 µm thickness were made. Immunostaining of MMP-9 was done using 10 ml of ready to use IgG Rabbit Monoclonal (EP1255Y) Antibody to MMP-9 with 50 mg/ml of protein concentration. Section from bone marrow biopsy studied from 10 random individuals is used as positive control and cytoplasmic and nuclear staining of hematopoietic cells is regarded as positive for staining (Figure 1A). A negative control without the addition of a primary antibody is included in every batch of staining.

**Assessment of MMP-9 expression in gastric carcinoma**

At least 10 representative fields with maximum staining under high power magnification (400×) were chosen and 1000 cells were counted for each case. If the number of cells were less than 1000, then all the available cells were counted and results were expressed as a mean percentage. According to a study by Su-Zuan Chen et al. [15], cells exhibiting a brown-stained cytoplasm, at a higher intensity than the non-specific background staining were regarded as positively stained and tumors exhibiting positive staining in >10% of the total...
number of tumor cells were regarded as positive MMP-9 expression.

**Statistical analysis**

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software (IBM Corp., Armonk, NY). The Chi-square test was used for correlation between groups. Differences were assumed to be statistically significant if the p-value is <0.05.

**Results**

Out of 100 cases of gastric carcinoma, 69% showed positive expression (Figure 1C-1D) and 31% showed negative expression. MMP-9 expression in tumor tissue (69%) was compared with adjacent gastric mucosa (15%) and a statistically significant difference was found (p-value=0.000; Figure 1B). The expression of MMP-9 was correlated with various clinicopathological parameters. MMP-9 expression increases with tumor differentiation. Out of 38 cases of poorly differentiated tumors 28 cases (73.7%) show positive MMP-9 expression (p-value = 0.003). MMP-9 expression increases with the depth of invasion (T), 18 out of 22 cases (81.8%) of T4 shows positive expression (p-value=0.019). MMP-9 expression shows a significant correlation with the TNM stage. Forty-nine cases are grouped in TNM stage III-IV, in which 39 cases (79.6%) show positive MMP-9 expression (p-value = 0.025). The mean age in our study is 58 years and the mean tumor size is 5 cm. Based on the mean age and tumor size, the cut-off value for the age and tumor size in our study is taken as 58 years and 5 cm, respectively. MMP-9 expression was observed more in age <58 years (35 out of 48 cases, 72.9%). The size of the tumor is ≥5 cm in 56 cases of which 73.2% show positive expression of MMP-9. The correlation of MMP-9 expression and clinicopathological parameters is summarized in Table 1.

| Clinicopathological parameters | No of cases | MMP-9 + VE expression | P-value | Correlation |
|-------------------------------|-------------|------------------------|---------|-------------|
| **Age**                      |             |                        |         |             |
| <58 years                     | 48          | 35/48(72.9%)           | 0.416   | Insignificant |
| ≥58 years                     | 52          | 34/52(65.4%)           |         |             |
| **Sex**                      |             |                        |         |             |
| Male                          | 68          | 48/68(70.6%)           | 0.617   | Insignificant |
| Female                        | 32          | 21/32(65.6%)           |         |             |
| **Tumor size**               |             |                        |         |             |
| <5 cm                         | 44          | 28/44(63.6%)           | 0.306   | Insignificant |
| ≥5 cm                         | 56          | 41/56(73.2%)           |         |             |
| **Tumor site**               |             |                        |         |             |
| Cardia                        | 11          | 7/11(63.6%)            |         | Insignificant |
| Body                          | 20          | 14/20(70%)             | 0.920   | Insignificant |
| Antrum                        | 69          | 48/69(69.6%)           |         |             |
| **Histological types**       |             |                        |         |             |
| Intestinal                    | 80          | 55/80(68.8%)           | 0.914   | Insignificant |
| Diffuse                       | 20          | 14/20(70%)             |         |             |
| **Grade**                    |             |                        |         |             |
| Well                          | 5           | 0                      |         |             |
| Moderate                      | 57          | 41/57(71.9%)           | 0.003   | Significant |
| Poor                          | 38          | 28/38(73.7%)           |         |             |
| **Lymphovascular invasion**  |             |                        |         |             |
| Present                       | 52          | 36/52(69.2%)           | 0.959   | Insignificant |
| Absent                        | 48          | 33/48(68.7%)           |         |             |
| Primary tumor (T)             |             |                        |         |             |
**Discussion**

MMP-9 is a zinc-dependent enzyme present in the extracellular milieu and involved in the regulation of the tumor microenvironment. The tumor-stromal crosstalk mediated by various cytokines and growth factors enhances the expression of MMP-9 which causes altered proteolysis. The key event is the degradation of the extracellular matrix - basement membrane of the epithelial cells which forms the first barrier in tumor invasion, cancer progression, and metastasis in gastric carcinoma making it more lethal and vulnerable. Our study shows 69% positive expression and 31% negative expression. MMP-9 expression is correlated with age, sex, tumor size, site, histological types, lymphovascular invasion, tumor differentiation, depth of invasion (T), lymph node (N) metastasis, distant metastasis, and TNM stage. A significant statistical correlation was seen with tumor differentiation, depth of invasion, and TNM stage (p-value = 0.003, 0.019, and 0.025, respectively). In our study, increased MMP-9 expression was seen in cases with age <58 years (72.9%) and males (70.6%) which is in accordance with the study by Gao et al. in which 72.2% of cases with age <58 years and 76.2% of males show increased MMP-9 expression [16]. The average tumor size in our study is 5 cm and based on which tumor size is grouped into tumor size ≥5 cm (56 cases) and tumor size <5 cm (44 cases). The study observed increased expression in tumors ≥5 cm (41/56 cases, 73.2%). Body (14/20 cases, 70%) and antrum (48/69 cases, 69.6%) of the stomach show increased expression compared to the cardia. The study by Lee et al. found a significant correlation between Lauren histological types and MMP-9 expression with increased expression rate in intestinal-type [17]. However, our study shows increased expression in diffuse (14/20 cases, 70%) compared to intestinal (55/80 cases, 68.8%) type with no significant correlation. Our study shows increased expression in tumors with LV-invasion (69.2%). However, it is not statistically significant. In our study, we found increased expression in poorly differentiated tumors (28/38 cases, 73.7%) and 100% negative expression in well-differentiated tumors with statistically significant correlation (p-value=0.003). This shows that most of the poorly differentiated aggressive tumors show increased MMP-9 expression. The study by Zheng et al. shows significantly increased expression in advanced gastric carcinoma compared to early gastric carcinoma [18]. The study by Chu et al. [19] shows a significant correlation between depth of invasion and MMP-9 expression and in our study lymph node-positive cases shows increased expression (47/63 cases, 74.6%) compared to lymph node-negative cases (22/37 cases, 59.5%). However, it was not statistically significant (p-value = 0.114) [20]. In our study, six out of seven cases with distant metastasis show MMP-9 expression (85.7%). The studies by Sun et al., Zheng et al., and Chu et al. show a statistically significant correlation between TNM stage and MMP-9 expression [18-20]. Our study also shows increased MMP-9 expression with TNM Stage III-IV (39/49 cases, 79.6%) compared to stage I-II (30/51 cases, 58.8%) tumors with statistically significant correlation (p-value = 0.025). This shows most of the tumors in the advanced TNM stage show increased MMP-9 expression. We also compared the expression of MMP-9 between tumor tissue and adjacent normal gastric mucosa in 100 cases. In our study, tumor tissue showed increased expression (69%) compared to adjacent gastric mucosa (15%) with a statistically significant correlation (p-value = 0.000).

**TABLE 1: Correlation of MMP-9 expression with clinicopathological parameters**

|       | T1  | T2   | T3  | T4          |       |          |
|-------|-----|------|-----|-------------|------|----------|
|       | 3   | 47   | 48  | 22          | 0.019| Significant |
| Positive | 63  | 47/63(74.6%) | 63/93(67.7%) | 63 | 93/63(67.7%) | 0.321 | Insignificant |
| Negative | 37  | 22/37(59.5%) | 35/48(72.9%) | 22 | 18/22(81.8%) | 0.114 | Insignificant |
| Stage II | 51  | 30/51(58.8%) | 56/73(76.2%) | 56 | 30/56(53.6%) | 0.025 | Significant |
| Stage III | 49  | 39/49(79.6%) | 54/71(76.3%) | 54 | 34/54(63.0%) | 0.003 | Significant |

2021 R et al. Cureus 13(9): e18195. DOI 10.7759/cureus.18195
Conclusions
MMP-9 present in the extracellular matrix plays a vital role in tumor invasion and progression of gastric cancer by acting as a key messenger between tumor cells, stromal cells, and cytokines which forms the tumor microenvironment. MMP-9 expression in gastric carcinoma is correlated with various histopathological parameters. MMP-9 expression is significantly increased in poorly differentiated gastric carcinomas, tumors with serosal perforation, and TNM stage III-IV tumors. These findings in our study suggest there is a significant role for MMP-9 expression in the depth of primary tumor invasion, grade, and TNM stage of gastric carcinoma.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. The Institutional Ethics Committee (IEC), Sri Ramachandra University issued approval CSP-MED/15/JAN/21/01. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993, 54:594-606. 10.1002/ijc.2910540413
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991, 265:1287-9.
3. Brown LM, Devesa SS: Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002, 30:235-56. 10.1016/s1055-3207(02)00002-9
4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 2015, 65:87-108. 10.3322/canjonc.21262
5. Yasumitsu H, Miyazaki K, Uemura N, Umeda M: Comparison of extracellular matrix-degrading activities between 64-kDa and 90-kDa gelatinases purified in inhibitor-free forms from human schwannoma cells. J Biochem. 1992, 111:74-80. 10.1093/oxfordjournals.jbchem.a123721
6. Goldberg GI, Strongin A, Collier IE, Gennrich LT, Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collag enase, and activation of both proenzyme with stromelysin. J Biol Chem. 1992, 267:683-91.
7. Coussens LM, Werb Z: Inflammation and cancer. Nature. 2002, 420:860-7. 10.1038/nature04428
8. Yu W, Liu J, Xiong X, Ai Y, Wang H: Expression of MMP9 and CD44 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract. 2009, 205:709-15. 10.1016/j.prp.2009.05.010
9. Zeng ZS, Huang Y, Cohen AM, Guillem JG: Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996, 14:5133-40. 10.1200/jco.1996.14.12.5133
10. Sillanpää S, Anttila M, Voutilainen K, et al.: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol. 2007, 104:296-303. 10.1016/j.ygyno.2006.09.004
11. McGowan PM, Duffy MJ: Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 2008, 19:1566-72. 10.1093/annonc/mdn180
12. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr: Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1995, 7:1434-41. 10.1096/fasebj.7.15.826238
13. Yoo YA, Kang MH, Lee HJ, et al.: Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EM, and MMP-9 pathway in gastric cancer. Cancer Res. 2011, 71:7061-70. 10.1158/0008-5472.CAN-11-1358
14. Mori N, Sato H, Hayashibara T, et al.: Helicobacter pylori induces matrix metalloproteinase-9 through activation of nuclear factor kappaB. Gastroenterology. 2005, 124:983-92. 10.1053/gast.2003.50152
15. Chen SZ, Yao HQ, Zhu SZ, Li QY, Guo GH, Yu J: Expression levels of matrix metalloproteinase-9 in human gastric carcinoma. Oncol Lett. 2015, 9:915-9. 10.3892/ol.2014.2768
16. Gao XH, Yang XQ, Wang BC, Liu SP, Wang FB: Overexpression of twist and matrix metalloproteinase-9 with metastasis and prognosis in gastric cancer. Asian Pac J Cancer Prev. 2015, 14:5505-60. 10.7314/apjcp.2015.14.9.5505
17. Lee LY, Wu CM, Wang CC, et al.: Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histol Histopathol. 2008, 23:515-21. 10.14670/hh.23.515
18. Zheng H, Takahashi H, Murali Y, et al.: Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006, 26:3579-83.
19. Chu D, Zhang Z, Li Y, Zheng J, Dong G, Wang W, Ji G: Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer. 2011, 129:887-95. 10.1002/ijc.25734
20. Sun WH, Sun YL, Fang RN, et al.: Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol. 2005, 35:707-13. 10.1093/jjco/hyi196